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One of the major conceptual advances in the understanding of the pathogenesis of heart failure has been the insight that myocardial dysfunction
and heart failure may progress as the result of the sustained over-expression of nitric oxide (NO) metabolites locally and in blood modulated by
inducible nitric oxide synthase (iNOS). This by virtue of their deleterious effects is sufficient to contribute to disease progression by provoking left
ventricular (LV) remodeling, hypertrophy and progressive LV dysfunction. Recently, tumor necrosis factor-alpha (TNF-α) has also been identified
in this setting of heart failure. Analogous to the situation with NO, the over-expression of TNF-α is sufficient to contribute to disease progression
in heart failure phenotype. Although important interactions between TNF-α and the NO have been recognized in the cardiovascular system for
over a decade, the nature and importance of the interactions between these biologically active molecules in cardiac hypertrophy has become
apparent only in the recent times. Therefore, we focused on the prevailing updated evidence which suggests that there is a functionally significant
cross-regulation between NO and TNF-α signaling in blood thus playing a part in cardiac hypertrophy and failure. The discussions presented here
will have a bearing on the therapeutic potential via inhibitors of these pathways in reducing cardiomyocyte hypertrophy and the LV dysfunction.
© 2006 Elsevier B.V. All rights reserved.Keywords: TNF-α; Proinflammatory cytokines; Nitric oxide; Cardiomyopathy; Left ventricular function1. Introduction
In light of the data painstakingly gathered over the last 10 to
12 years, the relevance of the well-established experimental
models of myocardial dysfunction and failure overload to
human cardiovascular disease remains perplexing [1–4].
Typically heart failure is the final culmination of protracted
disease states (Fig. 1) precipitated by underlying hypertension,
ischemic changes and atherosclerosis, valvular insufficiency,
viral myocarditis or mutations in genes encoding sarcomericAbbreviations: ROS, indicates reactive oxygen species; NO, nitric oxide;
iNOS, inducible nitric oxide synthase; cNOS, constitutive nitric oxide synthase;
cGMP, cyclic guanine 3′,5′-monophosphate; O2
+, superoxide; GSH, glutathione;
NAD (P)H, Nicotinamide adenine dinucleotide phosphate (reduced form);
PKC, protein kinase C; ‘P’, indicates phosphorylated form; MMP, matrix
metalloproteinase; H2O2, hydrogen peroxide; Tnl, troponin I; S 1-P, sphingosine
1-phosphate
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doi:10.1016/j.bbadis.2006.09.002proteins [5]. However, with the advent of the unifying
understanding of the redox-inflammation interactions via
gain- and loss-of-function approaches, a reductionist investiga-
tive approach for defining the pathways and processes of
reactive myocardial adaptation became possible [discussed in
ref. [6]. In summarizing the literature there is almost a
consensus that augmentation, inhibition, or ablation of specific
signaling events through targeted gene deletion or over-
expression as being responsible for the various degrees of
myocardial failure [7–9].
Our understanding of the pathogenesis of the myocardial
dysfunction has evolved from viewing cardiac failure as an
illness resulting from the “defective pump” to the new concept
that one of the major determinants of the progression of heart
failure as the persistent over activation of various compensatory
systems involving reactive oxygen species (ROS) [10,11]. In
addition, other emerging evidence indicates that under conditions
of oxidative stress, the activation of the inflammatory system
occurs, resulting in the production and release of proinflamma-
Fig. 1. Delayed negative inotropic effects of reactive oxygen species (ROS) and TNF-α. Over the long term, TNF-α (1) increases production of iNOS with high-output
NO generation, (2) increases generation of ROS, and (3) induces mitogen-activated protein kinases (MAPK)-mediated phosphorylation with attenuation of
myofilament Ca2+. TNF-α also enhances tissue infiltration of inflammatory cells, which can serve as sources for ROS and iNOS-derived NO, and augment tyrosine
kinases/phosphatase and contractile dysfunction secondary to direct cell-to-cell interactions.
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of autoantibodies and over-expression of class II major
histocompatibility complex molecules as well as adhesion
molecules that may perpetuate the inflammatory state [12–14].
Tumor necrosis factor-alpha (TNF-α) though traditionally
considered cardio-depressant mediator, yet its contribution in
myocyte contractile responses is complex and bimodal, with an
early response of variable direction, (stimulatory or depressant),
depending on the ambient physiologic milieu and the relative
contributions of other underlying signaling pathways especially
nitric oxide (NO) [15,16]. This is subsequently followed by a
profoundly late cardio-depressant response lasting hours to days
depending on the production of secondary mediators and the
combined influence of NO generated from inducible nitric
oxide (iNOS), ROS and alteration in β-adrenergic receptor
signaling. Supportive evidence comes from the fact that partial
blockade of the rennin-angiotensin and β-adrenergic systems
leads to improved cardiomyocyte survival [17–19]. Hence, the
interrelationships between these pathways and the time
dependence of their activation are important considerations in
the evaluation of cytokine-dependent dysfunction during both
acute cardiac injury and chronic pathologies (Fig. 1). Certainly,
the stimuli are entirely different, as are the cellular responsesand it is not yet known what the important relevant
pathophysiological events are but accumulating data suggest
that they differ substantially [20–22]. Additionally, considering
that many of the data, by necessity, collected using genetically
altered mice, the basic differences between mice and humans
with respect to heart rate, cardiac reserve, and strain variations
mitigate against easy comparisons [discussed in ref [23].
Hence, the major focus of this review will be the regulation
and effects of TNF-α and NO in the modulation of myocardial
function and their potential involvement in the strain induced
mechanotransduction mechanism summarized in Fig. 2. The
discussion will provide rationale for the sometimes-conflicting
results in the literature regarding the underlying mechanisms
and patterns of myocardial dysfunction.
1.1. TNF-α induced myocardial dysfunction
Accrued evidence indicates that cytokines are important
mediators of cardiovascular disease. A working understanding
of inflammatory cytokines and their relationship to myocardial
disease is of growing importance to basic and clinical
cardiovascular scientists, immunologists and clinicians. In this
regard, TNF-α is a proinflammatory cytokine that has been
Fig. 2. Redox-dependent pathways are regulated by cGMP-NO, reactive oxygen species (ROS) and tumor necrosis factor-alpha (TNF-α) to initiate cardiac failure. The
activation of the TNF-α-receptors by circulating soluble TNF-α results in the activation of a number of cell signaling pathways. Specific pathways include those that
result in the production of activator protein-1 (AP-1) and nuclear factor kappa B (NF-κB) transcription factors. Activation of cell surface TNF-α receptors may
therefore result in increased transcription factor production and enhancedMMP gene transcription. Both of these pathways converge on overlapping mitogen-activated
protein kinases (MAPK) signal transduction pathways. Angiotensin II stimulates production of intracellular ROS primarily through activation of multi-subunit NAD
(P)H oxidase. Intracellular ROS modify the activity of tyrosine kinases (Src, Ras, JAK2, Pyk2, P13-K and epidermal growth factor receptors) as well as MAPK, c-Jun
N terminal kinase (JNK). Activation of these redox-sensitive pathways results in numerous cellular responses, which if uncontrolled, could contribute to vascular
damage, myocytes dysfunction due to stimulatory effect of MMP matrix metalloproteinases.
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including acute myocardial infarction, chronic heart failure,
atherosclerosis, viral myocarditis, cardiac allograft rejection and
septic cardiac dysfunction [24–27]. Initially, TNF-α was
described as predominantly the product of lipopolysacchar-
ides-stimulated macrophages where NF-κB activation is
necessary for the induction of iNOS and expression of TNF-
α. Evidence now indicates that cardiac myocytes themselves
produce substantial amounts of TNF-α in response to ischemia
[28].
The intracellular signal pathways that provoke TNF-α
production are being elucidated with increasing clarity.
Evidence from a transgenic mouse model indicated that TNF-
α over-expression causes shock due to a decrease in peripheral
vascular resistance and direct cardiac effects [29]. Mann and his
colleagues have argued that the net effect of TNF-α on cardiac
function will depend on the amount and duration of TNFαexpression [29]. Short-term expression of TNF-α within the
heart may be an adaptive response to ‘stress’, whereas long-term
expression may be maladaptive resulting in cardiac decompen-
sation. Several investigators have also demonstrated that
infusions of micromolar concentrations (40–200 μg/kg) of
TNF-α can produce left ventricular dysfunction [30,31],
cardiomyopathy, and the clinical manifestation of heart failure.
In addition, TNF-α can affect heart failure, in part, by
stimulating myocyte hypertrophy, through the generation of
ROS intermediates in cardiac myocytes, and also by inducing
ventricular remodeling, through stimulating extracellular matrix
protein production and increased turnover of the matrix
metalloproteinases [32,33]. TNF-α can also cause cardiomyo-
cytes loss, through necrosis, or apoptosis, as demonstrated by
in vitro models. It can induce apoptosis directly, via the TNF
receptor, or indirectly, through stimulation of NO production
[15,34].
8 M. Elahi et al. / Biochimica et Biophysica Acta 1772 (2007) 5–14It is suggested that TNF-α can depress myocardial function
through NO-dependent pathways [35]. Activation of the NO-
dependent pathway can induce negative inotropic effects on
isolated cardiac myocytes, causing immediate cell contraction,
through stimulation of iNOS production [36]. The resultant
increase in NO will act as an important intracellular signaling
molecule that mediates the negative inotropic effects. Reports
have recommended that TNF-α, infused at low non-toxic
concentrations (<2.5 μg/kg), depresses myocardial contractile
performance independently of NO, through blocking α- and β-
adrenoceptor-stimulated contractility [discussed in ref [37].
Several other studies have analyzed the effects of TNF-α on
myocardial calcium handling as one mechanism of TNF-α-
induced contractile dysfunction [38,39]. TNF-α-induced
disruption of calcium handling may lead to dysfunctional
excitation–contraction coupling causing systolic and/or dia-
stolic dysfunction. The actions of TNF-α on left ventricular
dysfunction were shown to be reversible in animal models
[40–43].
1.2. Effects of NO on inducing left ventricular dysfunction
NO imparts cardiac effects via two general signaling
modalities: (1) the activation of soluble guanylate cyclase and
the subsequent formation of cGMP, which in turn activates
protein kinase G (PKG) and PKG-dependent phosphorylation
events; and (2) the direct oxidation of thiol residues on critical
regulatory proteins (S-nitrosylation) [44,45]. At nanomolar
concentrations of NO, levels that are lower than those required
to promote S-nitrosylation, this blocks mitochondrial respira-
tion through direct and sensitive inhibition of cytochrome-c
oxidase (complex IV of mitochondrial respiration) [46]. Since
myocytes are cells packed with mitochondria, bioavailability of
NO at nanomolar concentrations could have significant
implications on myocardial function [46]. These events induce
complex myocardial functional responses that include bimodal,
concentration-dependent effects on contractility and the Ca2+
transient, desensitization of the myofilaments to Ca2+ , and
suppression of mitochondrial respiration. A large number of
studies, performed in a variety of experimental models, have
examined whether NO, contributes to early cytokine-induced
contractile dysfunction. These investigations have yielded
variable (and sometimes conflicting) results. In a study of
isolated, superfused hamster papillary muscles, Finkel et al. [15]
demonstrated that relatively high concentrations of TNF-α,
profoundly depressed contractile function within 5 min, and that
these effects were fully reversible on washout. The nonspecific
NOS inhibitor NG-monomethyl-L-arginine blocked these
effects, a response that was overcome by the addition of excess
L-arginine. The rapid time course and reversibility of these
effects implicated the activation of myocardial NOS. Since this
initial report, several additional studies have supported a role for
NO in the early negative inotropic effects of the TNF-α and/or
IL-1β (alone or in combination) in adult and neonatal mam-
malian myocytes, guinea pig, and rat muscle strips, isolated
crystalloid-perfused rat hearts, and human atrial trabeculae
[47–52].In addition to acute contractile dysfunction, NO has been
linked to a variety of functional abnormalities in the depression
of the Ca2+ transient [53,54], TNF-α-mediated reductions in
myofilament Ca2+ sensitivity [47], and the deterioration of
mechanical efficiency induced by a combination of IL-1β,
TNF-α and IFN-γ [52]. Several authors have further shown that
these NO-mediated responses were cGMP dependent, requiring
activation of soluble guanylate cyclase [49,53]. Importantly,
Kumar et al. [49] demonstrated that although TNF-α and IL-1β
increased the myocyte generation of NO gas, there was no
difference in Ca2+ -dependent (or independent) NOS activity
measured in vitro. This suggested that cytokines impact NOS
activity by regulating cofactor and substrate conditions rather
than via increases in abundance or fixed post-translational
enzyme modifications. The above-mentioned studies have
evaluated a wide range of cytokine concentrations (picomolar
to nanomolar) and have uniformly used pharmacological NOS
blockade and/or NO scavengers to probe the role of NO [55,56].
To date, no studies have been performed in mice with genetic
ablation of the NOS isoforms, an investigation that would
provide the most conclusive delineation of the role of NOS in
early cytokine-mediated contractile dysfunction.
Although these studies persuasively argue that NO has an
important role in the pathogenesis of acute cytokine-mediated
contractile dysfunction, they stand in direct contrast to several
reports that dispute this concept [54,57–59]. In isolated adult
feline left ventricles and cardiomyocytes, Yokoyama et al. [59]
demonstrated that TNF-α-dependent immediate reductions in
contractility and Ca2+ transients were not accompanied by
increased NO oxidation products or cGMP production.
Furthermore, the contractile dysfunction was not prevented by
two different pharmacological NOS inhibitors. Other studies
examining TNF-α and/or IL-1β in isolated rat hearts and guinea
pig myocytes have similarly failed to show an acute increase in
NO oxidation products or cGMP and have also reported no
effect of NOS inhibition on early cytokine-mediated cardio-
depression [57,58]. The basis for the discrepancies between
these studies is not entirely clear but may be related to species
differences and differences in experimental models and
conditions. Importantly, the magnitude of NOS activation may
be cytokine specific. In this regard, Sugushita et al. [54] have
demonstrated that in guinea pig myocytes, whereas both IL-6
and TNF-α reduced cell shortening and peak systolic Ca2+,
NOS blockade prevented IL-6-mediated effects but had no
effect on the response to TNF-α.
1.3. TNF-α depress cardiac efficiency via nitrosative mediated
mechanism
Some studies on isolated cardiomyocytes have described a
delayed cytokine-mediated depression of basal unstimulated
contractility, an observation that is in agreement with results
from other models such as in the left ventricles (LV) of isolated
hearts or in whole animals, multicellular preparations such as
papillary muscles and atrial trabeculae, and in transgenic mice
with cardiac-specific over-expression of TNF-α [65–67]. Most
studies have implicated cytokine-mediated induction of iNOS
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NO generation in the depression of basal mechanical function
[68,69].
In this context, modulation of basal function by NO may be
more dependent on S-nitrosylation of thiol residues of
regulatory proteins [60]. Consistent with this notion, studies
in isolated myocytes have demonstrated that the late contractile
dysfunction (24 to 48 h of exposure) induced by TNF-α is
linked to NO-dependent depression of the Ca2+ transient. In
addition, within a similar time frame interleukin (IL)-1 beta (IL-
1β) causes an NO-dependent (but cGMP-independent) inhibi-
tion of oxidant-sensitive mitochondrial enzymes and the inward
Ca2+ current resulting in the inhibition of mitochondrial
respiration, energy depletion, and depressed contraction [61–
64]. As S-nitrosylation is a redox-driven event, ambient levels
of ROS significantly modulate the ensuing covalent protein–
thiol modifications and the ultimate balance between nitrosative
and oxidative stress. If TNF-α stimulation induces high-output
iNOS, the high levels of NO generated would be expected to
result in secondary oxidative modifications in the presence of
superoxide. Studies have demonstrated an inducible NO
production originating from within the heart, and that TNF-
induced NO mediates alterations in cardiac contractility,
although the cytotoxic potential of NO with respect to the
heart has yet to be defined. Evidence from studies [63] suggest
that increased activity of an inducible nitric oxide synthase
(iNOS; type 2 NO synthase) in primary isolates of adult rat
ventricular myocytes after exposure to soluble mediators in
medium conditioned by lipopolysaccharide-activated macro-
phages is associated with a decrease in their contractile
responsiveness to beta-adrenergic agonists. However, the
studies failed to clarify specifically which inflammatory
cytokines in the medium contributed to the induction of iNOS
activity in myocytes and whether the induction of iNOS would
result in an obligatory decline in contractile function. In this
context, IL-1 beta and TNF-α were both reported to be present
in the lipopolysaccharide-activated macrophage-conditioned-
medium and therefore it is not clear whether both cytokines
were equally as effective in induction of iNOS.
Indeed, as in above, several studies have established that
cytokine-mediated contractile dysfunction results not only from
increased iNOS-derived NO but also from increased ROS
generation particularly from peroxynitrite formation. Using
isolated working rat hearts perfused with a Krebs–Henseleit
solution containing a combination of cytokines (5 ng/mL
human IL-1B, 9 ng/mL rat IFN-y, 20 ng/mL human TNF-α),
Ferdinandy et al. [65] demonstrated a marked decline in
myocardial contractility over 20 min. This was preceded by an
increased activity of superoxide sources such as xanthine
oxidoreductase and NAD (P) H oxidase pathways together with
an enhanced activity of iNOS. In addition, there was an
increased myocardial contents of NO, superoxide, and the
peroxynitrite markers nitrotyrosine and dityrosine. Further-
more, cardiac dysfunction and nitrotyrosine levels were
inhibited by concomitant administration (individually) of a
NOS inhibitor, superoxide scavenger, and peroxynitrite decom-
position catalyst.Studies using an in vivo canine model of IL-1β-mediated
chronic cardiac dysfunction have similarly demonstrated the
importance of superoxide and peroxynitrite [60]. Coronary
injection of IL-1β coated microspheres (but not control
microspheres) resulted in increased myocardial superoxide,
nitrotyrosine, and persistent LV dysfunction at 7 days, effects
that were prevented by concomitant treatment with dexameth-
asone, iNOS inhibition with aminoguanidine, or pharmacolog-
ical inhibition of superoxide production [65]. These authors also
suggested that inflammatory cells infiltrating in response to
cytokines may contribute to superoxide generation as inhibition
of the adhesion molecule P-selectin ameliorated the LV
dysfunction [66]. These findings are consistent with the
demonstration that cell-to-cell contact between inflammatory
cells (macrophages) and myocytes enhances the delayed
contractile dysfunction induced by the TNF-α because of the
production of ROS and NO [49]. As oxidative modifications
attributable to peroxynitrite would tend to be irreversible, post
hoc inhibition of NO generation would not be expected to
reverse the mechanical dysfunction. Indeed, whereas NOS
inhibitors given concurrently with cytokines improve the
delayed contractile dysfunction that is manifested in vivo
NOS inhibition after the establishment of cytokine-mediated
dysfunction does not acutely reverse the loss of contractile
function [57,67].
1.4. INOS-TNF-α intracellular signaling in heart failure
Mann et al. have argued that as TNF-α is produced following
all forms of cardiac injury, it may act as a stress response gene in
the heart [68]. Using mammalian hearts, TNF-α-mRNA was
induced within 30 min of a stressful stimulus with endotoxin
challenge and TNF-α-mRNA levels returned to baseline levels
soon after the removal of the stimulus [69,70]. TNF-α
stimulation of cultured cardiac myocytes resulted in increased
heat shock protein (HSP 72) expression that was completely
abolished by a neutralizing antibody against TNF-α [71]. Very
high concentrations of TNF-α (>100 U/mL) in physiological
condition resulted in lower levels of HSP expression via the
modulation of the iNOS activity [71]. Similarly, immunoreac-
tivity for NO has been demonstrated in myocardial dysfunction
and that the increased levels of iNOS in heart failure coincided
with elevated TNF-α level (>50 U/mL) not present in ischemic
heart disease or normal myocardium [31]. However, the
stimulus for this mechanism in patients with chronic heart
failure remains unclear, but may be related to the local ischemia
associated with reduced blood flow. In vitro experiments on
perfused hearts suggest that the resultant oxidation products
(H2O2, ONOO
−, O2
.−, etc.), CREB/activating transcription
factor (ATF) family, Ser133 phosphorylation products may
induce TNF-α production. Ser133 phosphorylation products are
mediated by a variety of protein kinase pathways such as (1)
protein kinase A (PKA), (2) Ca2+/calmodulin-dependent
protein kinase (CaMK) II, (3) extracellular signal-regulated
kinase (ERK), (4) p38 mitogen-activated protein kinase (p38-
MAPK), and (5) phosphatidylinositol 3-kinase (PI3K)} may
activate a P38 mitogen activated protein kinase (MAPK) [72].
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the signaling cascade during heart failure may contribute to the
production and release of macrophage-derived proinflammatory
mediators. Under normal circumstances, lipopolysaccharides
(LPS) interaction with CD14 is an obligate trigger of the
intracellular signals that transmit LPS-induced TNF production.
LPS–CD14 interaction provokes rapid activation of protein
tyrosine kinase (PTK) causing tyrosine phosphorylation of
several intracellular protein kinases [73,74]. PTK activates a
pathway involving Ras/Raf-1/mitogen-activated protein kinase
kinase (MEK)/MAPK/NF-κB [75]. Several studies have
demonstrated that LPS activates PTK and that PTK inhibition
abolishes downstream activation of MAPK, TNF and IL-1
production, and macrophage-mediated tumoricidal activity. An
early target of activated PTK is Ras that is able to interact
directly with Raf-1 [76], which is an important intermediate of
MAPK activation. Studies by Reimann and colleagues [76]
demonstrated that LPS resulted in PTK-dependent rapid
phosphorylation and activation of Raf-1. These findings were
supported by Geppert and associates [77], who observed that
transfection of the dominant-negative repressors of Ras and
Raf-1 into macrophages, resulted in a suppression of LPS-
induced activation of the TNF promoter. However, transfection
with a constitutively active form of Raf-1 did not reproduce
LPS-induced macrophage activation, suggesting that Raf-1
activation is necessary but not sufficient to induce macrophage
TNF production. Raf-1/MEK appears to activate members of
the MAPK family of protein kinases; of these the P38 MAPK
appears to be a pivotal MAPK in the cascade leading to TNF
gene induction [78]. Thus LPS interaction with CD14 may lead
to rapid intracellular tyrosine phosphorylation of Ras, a process
that initiates the protein kinase cascade leading to NF-κB
activation and TNF production during heart failure.
1.5. Evidence from in vivo studies
The view that proinflammatory cytokines induce LV
dysfunction was first gleaned from animal and human studies
of sepsis. These established circulating myocardial depressant
substances, later identified, in large parts, caused that sepsis-
associated cardiac dysfunction to be inflammatory cytokines
(including TNF-α IL-1β, IL-6, IL-2, and interferon-γ [IFN-γ])
[26,27]. In intact animals, intravenous administration of TNF-α
[79–81] recapitulated the hemodynamic changes of endoto-
xemia and endotoxic shock, and anti-TNF-α antibodies [25]
ameliorated the cardiovascular abnormalities and mortality. In
addition to these insights from studies of sepsis, it was noted
that immunomodulatory therapy for cancer using TNF-α was
limited by dose-dependent cardiovascular depression and
negative inotropy (1 to 200 μg/m2 body surface area by
alternating intramuscular and intravascular bolus injections)
[82,83]. These observations were extended by studies in rats
demonstrating that sustained infusion of TNF-α caused time-
dependent contractile dysfunction and LV dilatation that was
partially reversed by stopping the infusion or on concomitant
treatment with a TNF-α antagonist [31]. This concept was
subsequently confirmed by the observation that cardiac-specificTNF-α over-expression in mice induced LV dilatation, reduced
ejection fraction, depressed catecholamine responsiveness, and
induced premature mortality [32].
Several studies have specifically evaluated the in vivo effects
of cytokines on cardiac function, often using TNF-α. Early
studies in conscious dogs indicated that a single infusion of
recombinant human (rh) TNF-α resulted in the appearance of
LV systolic dysfunction 2 h to 2 days post-infusion as assessed
by the load-sensitive index LV ejection fraction that could
persist for up to 10 days, depending on the dose administered
[81]. The decline in left ventricular ejection fraction was not
normalized by volume resuscitation, suggesting intrinsic
cardiac dysfunction rather than a preload-dependent response.
Subsequent investigations using LV pressure-volume (or
pressure-dimension) indexes confirmed the delayed onset of
LV dysfunction following TNF-α infusion (from 2 to 24 h after
initiation of the infusion, depending on the contractile parameter
examined), as assessed by the relatively load-independent
parameters end-systolic elastance (Ees), preload-recruitable
stroke work (PRSW), or peak dP/dt normalized for end-
diastolic volume (EDV) [40–42]. Reduced LV performance has
also been associated with several diastolic abnormalities
including slowing of relaxation, LV dilatation without changes
in end-diastolic pressure (myocardial creep), and a leftward shift
of the end-diastolic pressure–strain relation, indicating in-
creased diastolic stiffness. Generally, cytokine-mediated con-
tractile dysfunction is reversible over an extended time period of
several days following exposure [31,81].
In contrast, the few studies that have examined the
immediate contractile effects of cytokines in vivo have
generally reported a distinct early stimulatory effect of TNF-
α on inotropy and lusitropy [40,41]. Specifically, within the
first 1 to 3 h after TNF-α administration, there is an augmen-
tation of several contractility indexes including Ees, the slope
of the dP/dtmax–EDV relation, and dP/dtmax normalized for
EDV, together with a leftward shift of the PRSW relation and a
reduction in the time constant of relaxation [41]. Importantly,
the increase in contractility and lusitropy was not related to
variations in heart rate or to cardiovascular reflex responses, as
they persisted in the presence of β-AR and vagal blockade,
and occurred before the maximal surge in circulating cate-
cholamines [41].
Thus, taken together, the aforementioned in vivo studies
indicate that TNF-α induce a biphasic effect on intrinsic cardiac
function comprised of an early positive inotropic and lusitropic
effect of relatively short duration, followed by a delayed and
prolonged phase of profound systolic and diastolic dysfunction.
The rapid onset of the early stimulatory response as early as 5 to
15 min in one study [41]) suggests a direct myocardial effect via
mechanisms not requiring gene expression, whereas the delayed
onset and prolonged duration of the late cardiodepressant
response suggest an indirect effect requiring the induction of de
novo gene expression and protein synthesis and the activation of
secondary mediators. Generally, proinflammatory cytokines can
be considered to impart negative inotropic and cardiodepressant
effects in pathophysiological states with sustained, chronic
augmentation of cytokine expression.
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Analogous to investigations in vivo, a biphasic contractile
response has also been observed in single myocyte, muscle strip,
and isolated heart preparations, with early effects generally
within 30 min and delayed effects occurring thereafter up to 48
to 72 h. These studies have uniformly reported delayed cytokine-
mediated depression of either basal [57,67] or stimulated [63,64]
myocardial function, but have reported conflicting results
regarding the immediate effects, with the preponderance of in
vitro and ex vivo studies also indicating early cytokine-induced
cardio-depression. Pressure-volume studies of the isolated,
blood-perfused canine heart have shown that TNF-α acutely
impacts LV mechanoenergetics by increasing the oxygen cost of
contractility, an effect ascribed to alterations in energy utilization
for excitation–contraction (E–C) coupling [84]. Coronary
vasoconstriction also contributes indirectly to TNF-α-induced
early [63,64] and late [67] contractile dysfunction in isolated,
crystalloid-perfused rat hearts.
The basis for the sometimes discrepant results in the
aforementioned studies regarding the immediate inotropic
effects of cytokines is not fully clear but may be related to
several factors like single myocyte, papillary muscle, and
isolated heart models which can inherently be less physiological
than the intact state, which is subject not only to direct
myocardial effects but also to complex and integrated vascular,
neural, hematologic/immunologic, and endocrinologic changes
effected by the TNF-α. From an alternative physiological
context, TNF-α primarily acts locally to induce effects that are
determined not only by the target cell type but also by the
prevailing cellular and biological milieu [85]. Furthermore,
TNF-α are generally not elaborated in isolation but rather as part
of a complex network involving multiple other cytokines and
biologically active molecules [20,21,26]. As TNF-α can have
additive, synergistic, or antagonistic effects [26,80], this will
complicate the responses seen in vivo or in blood-perfused ex
vivo models, such that the end-effects may not be determined
solely by the index cytokine. Also the ambient cellular redox
and/or metabolic state and impacted NO bioavailability should
be considered [86] under the circumstances. Therefore, careful
attention needs to be focused on the experimental methodology
and cytokine concentrations used. In vitro studies perspective
suggest that an immediate positive inotropic effect (when
reported) generally occurs very early (within 5 to 15 min) after
exposure and at lower cytokine concentrations [67,86] whereas
negative inotropic effects become pronounced with longer pe-
riods of exposure and/or higher concentrations. Finally, Stamm
and co-workers have reported significant species-specificity
with regard to the inotropic effects of recombinant cytokines;
this factor may also account for some of the variability among
studies that have used cross-species sources of cytokines [87].
1.7. TNF-α induced modulation of cardiac function: specific
target for intervention
Normal myocardium does not contain TNF-α, but expresses
both its receptors-TNF receptor types 1 and 2. However, infailing myocardium, there is increased expression of TNF-α and
the receptors for TNF-α are downregulated as discussed earlier.
Furthermore, in the patient with heart failure, circulating levels
of TNF-α are elevated and increased levels are found as the
patient's heart failure (HF) worsens [discussed in ref [88]. These
observations in humans as well as evidence in experimental
animals that TNF-α was capable of inducing reversible
myocardial dysfunction resulted in the evaluation of the new
neurohormonal pathways as a target for therapeutic interven-
tion. Indeed, pilot studies have shown that pharmacologic
blockade of the biologic effects of TNF-α in human beings was
associated with improved functional status as well as with
improved myocardial infarction [89,90]. With these positive
results, clinical (RENAISSANCE and RECOVER) trials
depicted findings in patients with moderate to severe heart
failure treated with anti-TNF-α blocking agents (Etanercept and
Infliximab). Hitherto, the clinical results of these trials were
disappointing. Two important notions could possibly explain
this conflicting paradigm; Firstly, studies on isolated myocytes
have shown that TNF-α acts as a growth stimulus and protects
myocardial cells from hypoxia and helps to retain systolic
function. Thus it is likely that systolic protection in heart failure
is not the direct result of cardiac TNF-α expression. Hence in
patients with established HF, anti-TNF-α therapy may no longer
have the ability to change outcomes because injury at that stage
is not dependent on TNF-α expression only. Once persistent
activation of TNF-α result in hypertrophy and dilation, therapy
would only put patients at risk of potential side effects of the
therapy, with no potential clinical benefit. Secondly, the
immune system is redundant after HF is established and other
proinflammatory cytokines (IL-1, IL-6) known to be elevated
can participate and or substitute for the absence of TNF-α in the
anti-TNF-α treated patients.
1.8. Unresolved issues and perspectives
Although the NO-cGMP-TNF-α axis has been shown to
attenuate cardiac hypertrophy, full therapeutic exploitation of this
system faces at least two challenges, the first being concomitant
untoward events. For NO, these would include reaction with
superoxide, negative inotropic effects, and depressed mitochon-
drial respiration. Addressing these issues requires consideration of
features of cardiac NOS such as isoform identity, spatial
confinement, and substrate and cofactor availability. A better
understanding of myocardial factors that protect against nitrosa-
tive stress is also needed. For anti-TNF-α, which are used in
treating heart failure, receptor downregulation or uncoupling may
limit their effectiveness in restricting cardiac hypertrophy.
The second challenge arises from the observation that
although maladaptive signaling leading to LV hypertrophy may
be inexorably linked to apoptosis and heart failure, survival
pathways are likely to be activated as well. Thus, there is a need
to identify the “good” from the “bad” signaling events occurring
during maladaptive cardiac hypertrophy. For instance, although
the calcineurin–nuclear factor of activated T-cells (NFAT)
pathway is activated in pressure overload and over-expressing
calcineurin results in cardiac hypertrophy that progresses to
12 M. Elahi et al. / Biochimica et Biophysica Acta 1772 (2007) 5–14heart failure, calcineurin–NFAT has been linked to anti-
apoptotic events [91]. Also, it is important to look at the effects
of NO-cGMP-TNF-α related signaling on all aspects of cardiac
remodeling, including apoptosis, matrix deposition, gene
expression, metabolism, and contractile function. After all, the
pathogenesis of heart failure is complex, involving a host of
events that include alterations in sarcomeric proteins, interstitial
fibrosis, endothelial dysfunction, myocardial apoptosis, and
abnormalities in cardiomyocyte cell-to-cell connection, excita-
tion–contraction coupling, and mitochondrial morphology.
These unresolved issues highlight the need to move as far
“downstream” as possible in developing therapeutic strategies
based on exploiting any of the recently identified endogenous
anti-hypertrophic systems, not just those involving NO-cGMP-
TNF-α regulatory system. In this regard, deacetylase-dependent
transcriptional repression mediated by the atypical home-
odomain protein Hop, a recently identified growth-suppressing
transcriptional pathway in cardiomyocytes holds promise as a
therapeutic target [92]. Whether this or any as-yet-to-be
identified, pathway is predominantly an anti-maladaptive
pathway warrants further investigations.
2. Conclusions
TNF-α impact on cardiac mechanical function may be either
cardiostimulatory or cardiodepressant, depending on the
prevailing cellular and biological milieu, specifically with
regard to the redox and metabolic state, the magnitude of extra-
cardiac adaptive and reflex responses and the synergistic and/ or
counter-regulatory effects of several cytokines acting in concert.
All of these variables will thus influence TNF-α mediated
myocardial dysfunction and cardiac failure triggered by the
nitrosative stress together with persistent activation of NO-
dependent signaling pathways as depicted schematically in Fig.
2. However, we are just beginning to recognize the limitations
of these analyses, as well as the identification of the primary
genetic etiology; both have provided only limited insight into
understanding the resultant heart failure pathways or pathology.
To fully understand cardiovascular failure, we now realize that
the overall intracellular and intercellular regulatory networks in
terms of the localization of TNF-α will need to be described.
Wrapping the profiling data within the biological phenomenol-
ogy, a plausible effort should be put forth in delineating the
relative importance of complex interrelationships between the
various cellular mechanisms underlying TNF-α-NO-induced
functional effects on the heart, so that this understanding can be
successfully translated into more effective therapy.
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